Compare M&T Bank Corporation (MTB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Organon & Co. Common Stock — how do they compare? M&T Bank Corporation trades at $215.86 (market cap $31.47B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: M&T Bank Corporation is far larger — about 8.7× Organon & Co. Common Stock's market cap, and M&T Bank Corporation pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 99 Days and Organon & Co. Common Stock for 0 Days on average.
| MTB | OGN | |
|---|---|---|
Market Cap | $31.47B | $3.62B |
Volume | 743,357 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $254.09 | $13.81 |
52-Week Low | $178.63 | $5.70 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $47.83B | $11.04B |
Dividend Yield | 2.75% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.05, down 1.75% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a P/E of 11.54, and net income margin of 30.85%. Recent developments include a new Connecticut branch opening and AI investments to drive loan growth. Cash flow trends show operational strength despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and dividend stability, though technical weakness and competitive banking pressures pose near-term risks. Analyst consensus targets $258.92 (19.8% upside) with 31% buy ratings, but investors should monitor loan growth execution and interest rate sensitivity.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
